Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Cerilliant
Teva
Novartis
Healthtrust
Argus Health
Express Scripts
Baxter
Fuji
Chubb

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,916,131

« Back to Dashboard

Which drugs does patent 8,916,131 protect, and when does it expire?

Patent 8,916,131 protects VIZAMYL and is included in one NDA.

This patent has nineteen patent family members in eighteen countries.
Summary for Patent: 8,916,131
Title:Radiopharmaceutical composition
Abstract: The present invention relates to radiopharmaceuticals and in particular to a radiopharmaceutical composition comprising a compound of Formula (I): and polysorbate as an excipient. The radiopharmaceutical composition of the invention reduces problems encountered with prior art compositions comprising the same class of compounds. Also provided by the invention is a method for the preparation of the radiopharmaceutical composition of the invention as well as particular uses of the radiopharmaceutical composition. ##STR00001##
Inventor(s): Roed; Line (Oslo, NO), Peterson; Sarah Elizabeth (Amersham, GB)
Assignee: GE Healthcare Limited (Buckinghamshire, GB)
Application Number:12/673,602
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,916,131

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,916,131

PCT Information
PCT FiledAugust 28, 2008PCT Application Number:PCT/EP2008/061275
PCT Publication Date:March 05, 2009PCT Publication Number: WO2009/027452

International Patents Family Members for US Patent 8,916,131

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2008292201 ➤ Sign Up
Brazil PI0815129 ➤ Sign Up
Canada 2694084 ➤ Sign Up
China 101790387 ➤ Sign Up
Denmark 2182988 ➤ Sign Up
European Patent Office 2182988 ➤ Sign Up CA 2015 00008 Denmark ➤ Sign Up
European Patent Office 2182988 ➤ Sign Up C300723 Netherlands ➤ Sign Up
European Patent Office 2182988 ➤ Sign Up 15C0006 France ➤ Sign Up
European Patent Office 2182988 ➤ Sign Up 1590009-5 Sweden ➤ Sign Up
European Patent Office 2182988 ➤ Sign Up 2015006 Norway ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Queensland Health
UBS
Chinese Patent Office
Teva
Cerilliant
Federal Trade Commission
Julphar
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot